Mannose receptor‐derived peptides neutralize pore‐forming toxins and reduce inflammation and development of pneumococcal disease. Issue 11 (28th September 2020)

• Record Type: Journal Article
• Authors: Subramanian, Karthik; Iovino, Federico; Tsikourkitoudi, Vasiliki; Merkl, Padryk; Ahmed, Sultan; Berry, Samuel B; Aschtgen, Marie‐Stephanie; Svensson, Mattias; Bergman, Peter; Sotiriou, Georgios A; Henriques‐Normark, Birgitta
• Is Part Of: EMBO molecular medicine. Volume 12:Issue 11(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-28
• Subjects: calcium phosphate nanoparticles -- mannose receptor C type 1 -- pore‐forming toxins -- Streptococcus pneumoniae -- toxin inhibitory peptides; Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.202012695
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract: Cholesterol‐dependent cytolysins (CDCs) are essential virulence factors for many human pathogens like Streptococcus pneumoniae (pneumolysin, PLY), Streptococcus pyogenes (streptolysin O, SLO), and Listeria monocytogenes (Listeriolysin, LLO) and induce cytolysis and inflammation. Recently, we identified that pneumococcal PLY interacts with the mannose receptor (MRC‐1) on specific immune cells thereby evoking an anti‐inflammatory response at sublytic doses. Here, we identified the interaction sites between MRC‐1 and CDCs using computational docking. We designed peptides from the CTLD4 domain of MRC‐1 that binds to PLY, SLO, and LLO, respectively. In vitro, the peptides blocked CDC‐induced cytolysis and inflammatory cytokine production by human macrophages. Also, they reduced PLY‐induced damage of the epithelial barrier integrity as well as blocked bacterial invasion into the epithelium in a 3D lung tissue model. Pre‐treatment of human DCs with peptides blocked bacterial uptake via MRC‐1 and reduced intracellular bacterial survival by targeting bacteria to autophagosomes. In order to use the peptides for treatment in vivo, we developed calcium phosphate nanoparticles (CaP NPs) as peptide nanocarriers for intranasal delivery of peptides and enhanced bioactivity. Co‐administration of peptide‐loaded CaP NPs during infection improved survival and bacterial clearance in both zebrafish and mice models of pneumococcal infection. We suggest that MRC‐1 peptides can be employed as adjunctive therapeutics with antibiotics to treat bacterial infections by countering the action of CDCs. Synopsis: Cholesterol‐dependent cytolysins (CDCs) are major virulence factors for many pathogenic bacteria. Pneumolysin (PLY) is a CDC produced by the human respiratory pathogen Streptococcus pneumoniae . This study identifies peptides from the mannose receptor MRC‐1 that inhibit toxin function and reduce pneumococcal disease severity. The C‐type lectin domain 4 (CTLD4) of MRC‐1 interacts with the cholesterol binding loop of PLY. Peptides from CTLD4 of MRC‐1 competitively inhibit toxin‐induced lysis of host cells and reduce inflammation. Pre‐treatment of cells with peptides inhibits bacterial entry via MRC‐1, results in targeting of bacteria to autophagosomes, and enhances bacterial killing. Administration of peptide‐loaded calcium phosphate nanoparticles improves survival and reduces bacterial load in mice and zebrafish models of pneumococcal disease. Abstract : Cholesterol‐dependent cytolysins (CDCs) are major virulence factors for many pathogenic bacteria. Pneumolysin (PLY) is a CDC produced by the human respiratory pathogen Streptococcus pneumoniae . This study identifies peptides from the mannose receptor MRC‐1 that inhibit toxin function and reduce pneumococcal disease severity.